Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Paishi Lidan Granules is a traditional Chinese medicine (TCM) product developed and manufactured by Liaoning Jindan Pharmaceutical. It is an approved medication in China, primarily indicated for the treatment of cholecystitis (inflammation of the gallbladder) and cholelithiasis (gallstones). The formulation is based on a traditional herbal recipe designed to clear heat, resolve dampness, and promote the flow of bile. Clinically, it is used to alleviate symptoms such as right upper quadrant pain, jaundice, and digestive distress associated with damp-heat in the liver and gallbladder. The medicine works by stimulating gallbladder contraction and relaxing the sphincter of Oddi, which facilitates the expulsion of small biliary stones and improves bile drainage.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on paishi lidan granules.